UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                -----------------
                          
                                    FORM 6-K

                        REPORT OF FOREIGN PRIVATE ISSUER
                        PURSUANT TO RULE 13a-16 OR 15d-16
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934
                               ------------------
                          
                         For the month of October 2004

                        Commission File Number: 001-31368

                                 SANOFI-AVENTIS
                 (Translation of registrant's name into English)

                   174, avenue de France, 75013 Paris, FRANCE
                    (Address of principal executive offices)

     Indicate  by check mark  whether the  registrant  files or will file annual
reports under cover Form 20-F or Form 40-F.

                       Form 20-F  [X]                 Form 40-F     [ ]

     Indicate  by check mark if the  registrant  is  submitting  the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):_______

     Indicate  by check mark if the  registrant  is  submitting  the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):_______

     Indicate by check mark whether the registrant by furnishing the information
contained  in this  Form is  also  thereby  furnishing  the  information  to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                       Yes     [ ]                    No     [X]

     If "Yes" marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82-________









     On October 22, 2004,  Sanofi-Aventis  (formerly known as Sanofi-Synthelabo)
published   the  attached   notice  on  its  website   (www.sanofi-aventis.com),
announcing   that  as  at  Thursday,   October  21,  2004,   18.00  hours  (CET)
Sanofi-Aventis's  mandatory  offer for the shares in Hoechst  Aktiengesellschaft
has been accepted for 62,121 shares in Hoechst Aktiengesellschaft,  representing
less  than  0.01%  of the  share  capital  and  the  voting  rights  of  Hoechst
Aktiengesellschaft.

                                  EXHIBIT LIST

Exhibit No.                       Description
-----------                       -----------

Exhibit 99.1       Notice, dated October 21, 2004, announcing number of
                   Hoechst shares tendered into mandatory offer by
                   Sanofi-Aventis to the shareholders of Hoechst AG, as of
                   October 21, 2004 at 18:00 hours (CET).








                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


Dated: October 22, 2004                     SANOFI-AVENTIS


                                            By:     /s/ Jean-Claude Leroy       
                                               ---------------------------------
                                               Name:    Jean-Claude Leroy
                                               Title:   Senior Vice President &
                                                        Chief Financial Officer






                                  EXHIBIT INDEX

Exhibit No.                        Description
-----------                        -----------

Exhibit 99.1       Notice, dated October 21, 2004, announcing number of
                   Hoechst shares tendered into mandatory offer by
                   Sanofi-Aventis to the shareholders of Hoechst AG, as of
                   October 21, 2004 at 18:00 hours (CET).